tadalafil has been researched along with Abnormality, Heart in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmadi, A; Bigdelian, H; Ghaderian, M; Hosseinzadeh, M; Sabri, MR; Shoja, M | 1 |
| Bydlowski, SP; Clavé, MM; Lopes, AA; Maeda, NY; Thomaz, AM | 1 |
| Cohen, JL; Krishnan, US; Nees, SN; Rosenzweig, EB; Valencia, GA | 1 |
| Chen, J; Huang, T; Huang, X; Huang, Y; Xia, C; Zhang, C; Zhang, G; Zhuang, J | 1 |
| Chen, J; Huang, T; Huang, X; Huang, Y; Wu, S; Xia, C; Yao, H; Zhang, C; Zhang, G; Zhuang, J | 1 |
| Ahmed, AA; Elnakish, MT; Floyd, K; Janssen, PM; Mohler, PJ; Saad, NS | 1 |
3 trial(s) available for tadalafil and Abnormality, Heart
| Article | Year |
|---|---|
Comparison of the therapeutic effects and side effects of tadalafil and sildenafil after surgery in young infants with pulmonary arterial hypertension due to systemic-to-pulmonary shunts.
Topics: Cardiac Surgical Procedures; Child, Preschool; Echocardiography; Female; Heart Defects, Congenital; Heart Septal Defects, Ventricular; Humans; Hypertension, Pulmonary; Infant; Iran; Length of Stay; Male; Phosphodiesterase 5 Inhibitors; Pulmonary Artery; Sildenafil Citrate; Tadalafil; Treatment Outcome | 2017 |
Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease.
Topics: Adolescent; Adult; Cardiac Catheterization; Child; Dose-Response Relationship, Drug; Echocardiography; Female; Follow-Up Studies; Heart Defects, Congenital; Heart Ventricles; Humans; Hypertension, Pulmonary; Magnetic Resonance Imaging, Cine; Male; Microcirculation; Middle Aged; Phosphodiesterase 5 Inhibitors; Pulmonary Circulation; Pulmonary Wedge Pressure; Retrospective Studies; Sildenafil Citrate; Tadalafil; Treatment Outcome; Young Adult | 2019 |
[Effects of iloprost combined with low dose tadalafil in adult congenital heart disease patients with severe pulmonary arterial hypertension: a single-center, open-label controlled study].
Topics: Adolescent; Adult; Carbolines; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Iloprost; Male; Middle Aged; Tadalafil; Treatment Outcome; Young Adult | 2014 |
3 other study(ies) available for tadalafil and Abnormality, Heart
| Article | Year |
|---|---|
Sildenafil Use in Children with Pulmonary Hypertension.
Topics: Adolescent; Bronchopulmonary Dysplasia; Child; Child, Preschool; Familial Primary Pulmonary Hypertension; Female; Heart Defects, Congenital; Hernias, Diaphragmatic, Congenital; Humans; Hypertension, Pulmonary; Infant; Infant, Newborn; Male; Sildenafil Citrate; Tadalafil; Treatment Outcome; Vasodilator Agents | 2019 |
Effects of low doses of aerosolized iloprost combined with tadalafil in treatment of adult congenital heart disease with severe pulmonary arterial hypertension.
Topics: Administration, Inhalation; Adult; Carbolines; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Iloprost; Male; Tadalafil; Young Adult | 2014 |
The Effect of Sorafenib, Tadalafil and Macitentan Treatments on Thyroxin-Induced Hemodynamic Changes and Cardiac Abnormalities.
Topics: Animals; Blood Pressure; Cardiomyopathies; Disease Models, Animal; Echocardiography; Electrocardiography; Heart Defects, Congenital; Heart Rate; Hemodynamics; Male; Mice; Myocardial Contraction; Niacinamide; Organ Size; Phenylurea Compounds; Pyrimidines; Sorafenib; Sulfonamides; Tadalafil; Thyroxine | 2016 |